---
figid: PMC9113882__ECAM2022-4987323.006
pmcid: PMC9113882
image_filename: ECAM2022-4987323.006.jpg
figure_link: /pmc/articles/PMC9113882/figure/fig6/
number: Figure 6
figure_title: ''
caption: 'JP could protect renal function and inhibit disease activity in MRL/lpr
  mice. The dynamic changes of urinary protein (a) and urinary creatinine (b) concentrations
  in MRL/lpr mice during 7–16 weeks of test. The antibody titer of ANA (c), anti-dsDNA
  (d), and anti-Sm (e) in serum after 8 weeks of treatment. ∗P < 0.05 and ∗∗P < 0.01,
  compared with the Control group; #P < 0.05 and ##P < 0.01, compared with the Model
  group; n = 10.'
article_title: Jieduquyuzishen Prescription Attenuates Renal Fibrosis in MRL/lpr Mice
  via Inhibiting EMT and TGF-β1/Smad2/3 Pathway.
citation: Shan Wu, et al. Evid Based Complement Alternat Med. 2022;2022:4987323.
year: '2022'

doi: 10.1155/2022/4987323
journal_title: 'Evidence-based Complementary and Alternative Medicine : eCAM'
journal_nlm_ta: Evid Based Complement Alternat Med
publisher_name: Hindawi

keywords:
---
